Amgen Inc.

Isis Pharmaceuticals, Inc.

Richard A Lindberg

William James Boyle

Andrew A Welcher

Gary M Fox

Timothy D Bartley

Ella Magal

Vann P Parker

Kenneth W Dobie

Sanjay Bhanot

Thomas Charles Boone

Hai Yan

Shaw-Fen Sylvia Hu

Murielle M Veniant-Ellison

John R Shutter

Robert McKay

Sanjay K Pandey

Thomas C Boone

The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.

Compositions and methods relating to glucagon receptor antibodies

Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Modulation of forkhead box O1A expression

Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.

Eck receptor ligands

Growing community of inventors

Thousand Oaks, CA, United States of America

Richard A Lindberg